Pluri signs $4.2M NIAID contract to develop PLX-R18 cell therapy for H-ARS

Pluri Inc.

Three-year, $4.2M contract with NIAID to advance PLX-R18 for Hematopoietic Acute Radiation Syndrome (H-ARS).
Company will collaborate with U.S. DOD's AFRRI and Uniformed Services University of Health Sciences (USUHS).
Program funded by NIAID, part of the National Institutes of Health (NIH).
PLX-R18 is a potential novel treatment for radiation exposure from nuclear disasters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.